Tabelecleucel treated relapsed or refractory EBV+ PTLD patients achieved a 50.7% Objective Response Rate (ORR), 23.0-month Median Duration of Response (DOR), and Median Overall Survival (OS) of 18.4 months Safety findings consistent with prior studies with no reports of cytokine release…

— ASH data reinforce survival benefits of front-line AYVAKIT® (avapritinib) use in patients with advanced SM — — Bone density analyses reported in patients with advanced SM underscore disease-modifying effects of AYVAKIT — CAMBRIDGE, Mass., Dec. 7, 2024 /PRNewswire/ — Blueprint…

DUBAI, UAE, 7 december 2024 /PRNewswire/ — Bybit, ‘s werelds op één na grootste cryptocurrencybeurs qua handelsvolume, onthult in samenwerking met Block Scholes haar November Option Volatility Report, Hierin belicht het de opmerkelijke mijlpaal van Bitcoin (BTC) die de $ 100.000 heeft…

73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months NKTR-255 enhanced CAR T-cell kinetics with improved CD8+ CAR-T area under the curve (AUC) 0-15 days post-administration being 5.8-fold greater than placebo-controls SAN…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.